Skip to main content
Erschienen in: Medical Oncology 12/2014

01.12.2014 | Original Paper

Diagnostic role of circulating YKL-40 in endometrial carcinoma patients: a meta-analysis of seven related studies

verfasst von: Daye Cheng, Ying Sun, Hu He

Erschienen in: Medical Oncology | Ausgabe 12/2014

Einloggen, um Zugang zu erhalten

Abstract

In the past decade, several studies have suggested a possible link between circulating YKL-40 levels and endometrial carcinoma (EC), but have arrived at inconsistent results. Therefore, we conducted the present meta-analysis and aim to disclose a more comprehensive evaluation of the sensitivity, specificity, and diagnostic accuracy of YKL-40 in EC. We systematically searched PubMed, Embase, Web of Science, Science Direct, SpringerLink, EBSCO, Wanfang, and Chinese National Knowledge Infrastructure databases for studies that evaluated the diagnostic value of YKL-40 in endometrial cancer. The STATA software 12.0 and Meta-Disc software were used to test the heterogeneity and to evaluate the overall test performance. A total of seven studies including 234 EC cases and 300 controls were included in our meta-analysis. The summary estimates of YKL-40 for EC diagnosis indicated a moderately high diagnostic accuracy for circulating YKL-40, with a sensitivity of 0.74, a specificity of 0.87, a PLR of 5.74, a NLR of 0.30, a DOR of 19.14, and an AUC of 0.80. On the basis of our meta-analysis, therefore, circulating YKL-40 could be promising and meaningful in the diagnosis of EC.
Literatur
1.
2.
Zurück zum Zitat Dobrzycka B, Mackowiak-Matejczyk B, Kinalski M, Terlikowski SJ. Pretreatment serum levels of bFGF and VEGF and its clinical significance in endometrial carcinoma. Gynecol Oncol. 2013;128:454–60.PubMedCrossRef Dobrzycka B, Mackowiak-Matejczyk B, Kinalski M, Terlikowski SJ. Pretreatment serum levels of bFGF and VEGF and its clinical significance in endometrial carcinoma. Gynecol Oncol. 2013;128:454–60.PubMedCrossRef
3.
Zurück zum Zitat Wittenberger T, Sleigh S, Reisel D, et al. DNA methylation markers for early detection of women’s cancer: promise and challenges. Epigenomics. 2014;6:311–27.PubMedCrossRef Wittenberger T, Sleigh S, Reisel D, et al. DNA methylation markers for early detection of women’s cancer: promise and challenges. Epigenomics. 2014;6:311–27.PubMedCrossRef
4.
Zurück zum Zitat Renkema GH, Boot RG, Au FL, et al. Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. Eur J Biochem. 1998;251:504–9.PubMedCrossRef Renkema GH, Boot RG, Au FL, et al. Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. Eur J Biochem. 1998;251:504–9.PubMedCrossRef
5.
Zurück zum Zitat Fusetti F, Pijning T, Kalk KH, Bos E, Dijkstra BW. Crystal structure and carbohydrate-binding properties of the human cartilage glycoprotein-39. J Biol Chem. 2003;278:37753–60.PubMedCrossRef Fusetti F, Pijning T, Kalk KH, Bos E, Dijkstra BW. Crystal structure and carbohydrate-binding properties of the human cartilage glycoprotein-39. J Biol Chem. 2003;278:37753–60.PubMedCrossRef
6.
Zurück zum Zitat Rehli M, Krause SW, Andreesen R. Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics. 1997;43:221–5.PubMedCrossRef Rehli M, Krause SW, Andreesen R. Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics. 1997;43:221–5.PubMedCrossRef
7.
Zurück zum Zitat Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull. 2006;53:172–209.PubMed Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull. 2006;53:172–209.PubMed
9.
Zurück zum Zitat Baniyash M, Sade-Feldman M, Kanterman J. Chronic inflammation and cancer: suppressing the suppressors. Cancer Immunol Immunother. 2014;63:11–20.PubMedCrossRef Baniyash M, Sade-Feldman M, Kanterman J. Chronic inflammation and cancer: suppressing the suppressors. Cancer Immunol Immunother. 2014;63:11–20.PubMedCrossRef
10.
Zurück zum Zitat Johansen JS, Baslund B, Garbarsch C, et al. YKL-40 in giant cells and macrophages from patients with giant cell arteritis. Arthritis Rheum. 1999;42:2624–30.PubMedCrossRef Johansen JS, Baslund B, Garbarsch C, et al. YKL-40 in giant cells and macrophages from patients with giant cell arteritis. Arthritis Rheum. 1999;42:2624–30.PubMedCrossRef
11.
Zurück zum Zitat Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev. 2006;15:194–202.PubMedCrossRef Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev. 2006;15:194–202.PubMedCrossRef
12.
Zurück zum Zitat Liu X, Zhang Y, Zhu Z, Ha M, Wang Y. Elevated pretreatment serum concentration of YKL-40: an independent prognostic biomarker for poor survival in patients with colorectal cancer. Med Oncol. 2014;31:85.PubMedCrossRef Liu X, Zhang Y, Zhu Z, Ha M, Wang Y. Elevated pretreatment serum concentration of YKL-40: an independent prognostic biomarker for poor survival in patients with colorectal cancer. Med Oncol. 2014;31:85.PubMedCrossRef
13.
Zurück zum Zitat Tschirdewahn S, Reis H, Niedworok C, et al. Prognostic effect of serum and tissue YKL-40 levels in bladder cancer. Urol Oncol. 2014;32:663–9.PubMedCrossRef Tschirdewahn S, Reis H, Niedworok C, et al. Prognostic effect of serum and tissue YKL-40 levels in bladder cancer. Urol Oncol. 2014;32:663–9.PubMedCrossRef
14.
Zurück zum Zitat Schultz NA, Christensen IJ, Werner J, et al. Diagnostic and prognostic impact of circulating YKL-40, IL-6, and CA 19.9 in patients with pancreatic cancer. PLoS One. 2013;8:e67059.PubMedCentralPubMedCrossRef Schultz NA, Christensen IJ, Werner J, et al. Diagnostic and prognostic impact of circulating YKL-40, IL-6, and CA 19.9 in patients with pancreatic cancer. PLoS One. 2013;8:e67059.PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Wang D, Zhai B, Hu F, et al. High YKL-40 serum concentration is correlated with prognosis of Chinese patients with breast cancer. PLoS One. 2012;7:e51127.PubMedCentralPubMedCrossRef Wang D, Zhai B, Hu F, et al. High YKL-40 serum concentration is correlated with prognosis of Chinese patients with breast cancer. PLoS One. 2012;7:e51127.PubMedCentralPubMedCrossRef
16.
Zurück zum Zitat Itik V, Kemik O, Kemik A, et al. Serum YKL-40 Levels in patients with Gastric cancer. Biomark Cancer. 2011;3:25–30.PubMedCentralPubMed Itik V, Kemik O, Kemik A, et al. Serum YKL-40 Levels in patients with Gastric cancer. Biomark Cancer. 2011;3:25–30.PubMedCentralPubMed
17.
Zurück zum Zitat Fan JT, Li MJ, Shen P, et al. Serum and tissue level of YKL-40 in endometrial cancer. Eur J Gynaecol Oncol. 2014;35:304–8.PubMed Fan JT, Li MJ, Shen P, et al. Serum and tissue level of YKL-40 in endometrial cancer. Eur J Gynaecol Oncol. 2014;35:304–8.PubMed
18.
Zurück zum Zitat Peng C, Peng J, Jiang L, et al. YKL-40 protein levels and clinical outcome of human endometrial cancer. J Int Med Res. 2010;38:1448–57.PubMedCrossRef Peng C, Peng J, Jiang L, et al. YKL-40 protein levels and clinical outcome of human endometrial cancer. J Int Med Res. 2010;38:1448–57.PubMedCrossRef
19.
Zurück zum Zitat Thom I, Andritzky B, Schuch G, et al. Elevated pretreatment serum concentration of YKL-40: an independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer. Cancer. 2010;116:4114–21.PubMedCrossRef Thom I, Andritzky B, Schuch G, et al. Elevated pretreatment serum concentration of YKL-40: an independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer. Cancer. 2010;116:4114–21.PubMedCrossRef
20.
Zurück zum Zitat Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25.PubMedCentralPubMedCrossRef Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25.PubMedCentralPubMedCrossRef
22.
Zurück zum Zitat Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.PubMedCrossRef Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.PubMedCrossRef
24.
Zurück zum Zitat Diefenbach CS, Shah Z, Iasonos A, et al. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer. Gynecol Oncol. 2007;104:435–42.PubMedCrossRef Diefenbach CS, Shah Z, Iasonos A, et al. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer. Gynecol Oncol. 2007;104:435–42.PubMedCrossRef
25.
Zurück zum Zitat Fan JT, Si XH, Liao Y, Shen P. The diagnostic and prognostic value of serum YKL-40 in endometrial cancer. Arch Gynecol Obstet. 2013;287:111–5.PubMedCrossRef Fan JT, Si XH, Liao Y, Shen P. The diagnostic and prognostic value of serum YKL-40 in endometrial cancer. Arch Gynecol Obstet. 2013;287:111–5.PubMedCrossRef
26.
Zurück zum Zitat Si XH, Fan J, Liao Y, et al. Preliminary research of serum YKL-40 in the diagnosis of endometrial carcinoma. J Pract Gynecol. 2011;27:121–4. Si XH, Fan J, Liao Y, et al. Preliminary research of serum YKL-40 in the diagnosis of endometrial carcinoma. J Pract Gynecol. 2011;27:121–4.
27.
Zurück zum Zitat Zhang X, Yang C, Lv J. Expression and significance of serum HE4 and YKL-40 in patients with endometrial cancer. Progress Obstet Gynecol. 2011;20:377–80. Zhang X, Yang C, Lv J. Expression and significance of serum HE4 and YKL-40 in patients with endometrial cancer. Progress Obstet Gynecol. 2011;20:377–80.
28.
Zurück zum Zitat Wei P. Expression and clinical significance of YKL-40 in endometrial carcinoma. Peking: Peking Union Medical College; 2011. Wei P. Expression and clinical significance of YKL-40 in endometrial carcinoma. Peking: Peking Union Medical College; 2011.
29.
Zurück zum Zitat Geng X. The research of YKL-40 and CA125 in diagnosis of endometrial carcinoma. Guangxi: Guangxi Medical University; 2011. Geng X. The research of YKL-40 and CA125 in diagnosis of endometrial carcinoma. Guangxi: Guangxi Medical University; 2011.
30.
Zurück zum Zitat Yu M. The preliminary investigation of YKL-40 in the diagnosis of endometrial carcinoma. Sichuan: Sichuan University; 2007. Yu M. The preliminary investigation of YKL-40 in the diagnosis of endometrial carcinoma. Sichuan: Sichuan University; 2007.
31.
Zurück zum Zitat Chung HH, Kim JW, Park NH, et al. Use of preoperative serum CA-125 levels for prediction of lymph node metastasis and prognosis in endometrial cancer. Acta Obstet Gynecol Scand. 2006;85:1501–5.PubMedCrossRef Chung HH, Kim JW, Park NH, et al. Use of preoperative serum CA-125 levels for prediction of lymph node metastasis and prognosis in endometrial cancer. Acta Obstet Gynecol Scand. 2006;85:1501–5.PubMedCrossRef
32.
Zurück zum Zitat Moore RG, Jabre-Raughley M, Brown AK, et al. Comparison of a novel multiple marker assay vs the risk of malignancy index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol. 2010;203(228):e1–6. Moore RG, Jabre-Raughley M, Brown AK, et al. Comparison of a novel multiple marker assay vs the risk of malignancy index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol. 2010;203(228):e1–6.
33.
Zurück zum Zitat Mitsuhashi A, Matsui H, Usui H, et al. Serum YKL-40 as a marker for cervical adenocarcinoma. Ann Oncol. 2009;20:71–7.PubMedCrossRef Mitsuhashi A, Matsui H, Usui H, et al. Serum YKL-40 as a marker for cervical adenocarcinoma. Ann Oncol. 2009;20:71–7.PubMedCrossRef
34.
Zurück zum Zitat Chudecka-Glaz AM, Cymbaluk-Ploska AA, Menkiszak JL, et al. Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer. J Ovarian Res. 2014;7:62.PubMedCentralPubMedCrossRef Chudecka-Glaz AM, Cymbaluk-Ploska AA, Menkiszak JL, et al. Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer. J Ovarian Res. 2014;7:62.PubMedCentralPubMedCrossRef
35.
Zurück zum Zitat Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. 2003;56:1129–35.PubMedCrossRef Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. 2003;56:1129–35.PubMedCrossRef
Metadaten
Titel
Diagnostic role of circulating YKL-40 in endometrial carcinoma patients: a meta-analysis of seven related studies
verfasst von
Daye Cheng
Ying Sun
Hu He
Publikationsdatum
01.12.2014
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 12/2014
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0326-8

Weitere Artikel der Ausgabe 12/2014

Medical Oncology 12/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.